Research points to a microRNA called miR-486 that plays an important role in a variety of aptamer tumors, but its mechanism of action in lung cancer is unknown; this study suggests that miR-486 is a promising tumor suppressor in lung cancer therapy; the findings suggest that this small molecule RNA could be used as a biomarker in lung cancer patients for targeting insulin growth factor inhibitor therapy for lung cancer patients. The findings, published in the journal Proceedings of the National Academy of Sciences (PNAS), suggest that miR-486 may serve as a biomarker for lung cancer patients who respond to insulin growth factor inhibitor therapy. A new study published by researchers from the Ohio State University Comprehensive Cancer Center, West China Hospital, Sichuan University, suggests that microRNA-486 in lung cancer is a potent oncogenic molecule that helps regulate the proliferation and migration of lung cancer cells and induces programmed cell death or apoptosis in these cancer cells, according to a report. The researchers demonstrated that microRNA-486 (miR-486) directly targets the insulin growth factor pathway, a pathway that is important for cell survival and proliferation, and also showed that alterations in this pathway have implications for early tumorigenesis and oncogenesis. The researchers also found that miR-486 itself is regulated by the tumor suppressor gene p53, which is the most frequently mutated gene in human cancers, and that the activity of miR-486 identified in this study is also partially dependent on functional p53. The findings, published in the journal Proceedings of the National Academy of Sciences (PNAS), suggest that miR-486 may be useful as a treatment for biomarkers in lung cancer patients who respond to insulin growth factor inhibitor therapy. ”It was previously unclear whether miR-486 functions as an oncogenic or oncogenic factor in lung cancer,” said Patrick Nana-Sinkam of Ohio State University, co-corresponding author of the article. ”miR-486 appears to be a biomarker for lung cancer, but its mechanism of action remains unclear,” he said, “whereas this latest finding suggests that miR-486 has a cancer-suppressive role in lung cancer cells and that miR-486 activity is partially dependent on p53 “. ”The mechanism of action of one oncogenic factor partially dependent on another was surprising to us,” said Carlo M. Croce, director of the Human Cancer Genetics Program at Ohio State University and lead scientist on the study, “and we don’t yet know what that means. If anything, it may have important implications for targeted therapy.” MicroRNAs are a class of short, non-coding RNAs that regulate the translation and degradation of mRNAs, thereby affecting the expression of proteins by cells. Studies have shown that certain small molecules of RNA are frequently abnormal in cancer. In this study, researchers analyzed lung tumor samples from 81 patients with stage 1 non-small cell lung cancer and tumor cell lines. From these, they found the most reduced miRNA, miR-486, which was the subject of the study.